bivalent HPV vaccine

BIOLOGICAL4 trials

Sponsors

London School of Hygiene and Tropical Medicine, Xiamen University, Zagazig University, Zhejiang Provincial Center for Disease Control and Prevention

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaCondylomata AcuminataHPV InfectionHuman Papilloma VirusWarts

Phase 2

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

RecruitingNCT05291845

Zagazig UniversityHuman Papilloma Virus, Warts

Start: 2022-04-03End: 2025-12-06Target: 162Updated: 2025-06-12

Phase 3

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

Active, not recruitingNCT02834637

London School of Hygiene and Tropical MedicineHuman Papilloma Virus

Start: 2017-02-23End: 2027-03-01Updated: 2026-09-08

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Active, not recruitingNCT04537156

Xiamen UniversityCervical Cancer, Cervical Intraepithelial Neoplasia, Condylomata Acuminata

Start: 2020-09-05End: 2027-12-31Updated: 2025-11-21

Phase 4

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

Active, not recruitingNCT07281677

Zhejiang Provincial Center for Disease Control and PreventionHPV Infection

Start: 2025-12-20End: 2029-11-13Updated: 2026-06-11

Related Papers

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls

Vaccine2026-06-30

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial.

2025-12-19

Congenital hyperextension of the knee without dislocation in a child: A case report

Journal of Clinical Images and Medical Case Reports2023-11-25

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.

2022-11-299 citations

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.

2022-10-0174 citations

Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.

2022-10-0147 citations

Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.

2021-09-2737 citations